Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
暂无分享,去创建一个
Andrew R Willan | Anastasios A Tsiatis | Ameet Bakhai | Andrew H Briggs | Mark A Hlatky | Michael F Drummond | Robert M Califf | Shelby D Reed | Kevin J Anstrom | Bernie J O'Brien | Ari Gnanasakthy | Henry A Glick | David J Cohen | Daniel B Mark | A. Gnanasakthy | M. Drummond | B. O'brien | R. Califf | A. Tsiatis | K. Anstrom | D. Mark | K. Schulman | H. Glick | A. Briggs | M. Hlatky | A. Willan | F. Torti | D. Cohen | S. Reed | Kevin A Schulman | A. Bakhai | Frank M Torti | D. Cohen
[1] B. O'brien,et al. Cost–effectiveness analysis for multinational clinical trials , 2005, Statistics in medicine.
[2] B. O'brien,et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. , 2005, Health economics.
[3] A. Gnanasakthy,et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2004, American heart journal.
[4] Andrew R Willan,et al. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.
[5] Michael Drummond,et al. Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.
[6] Y. R. Wang,et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. , 2003, The American journal of managed care.
[7] Amiram Gafni,et al. Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. , 2003, Health policy.
[8] S. Yusuf,et al. Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003 .
[9] Ruth Brown,et al. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. , 2003, The Canadian journal of cardiology.
[10] M. Lens,et al. Economic evaluation in evidence-based practice , 2002, Expert opinion on pharmacotherapy.
[11] Robert M Califf,et al. Lessons learned from recent cardiovascular clinical trials: Part II. , 2002, Circulation.
[12] T. Kahan,et al. The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study , 2002, Journal of internal medicine.
[13] H. Glick,et al. PMI10 DANCING WITH THE DEVIL: THE IMPORTANCE OF SUB-GROUP ANALYSIS IN ECONOMIC EVALUATION , 2002 .
[14] M. Drummond,et al. Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .
[15] M A Koopmanschap,et al. Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.
[16] R. Califf,et al. International differences in treatment effects in cardiovascular clinical trials. , 2001, American heart journal.
[17] P A Poole-Wilson,et al. Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study , 2000, European journal of heart failure.
[18] A A Tsiatis,et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.
[19] R. Califf,et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.
[20] P. Pattynama,et al. International differences in health care costs in Europe and the United States: Do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism? , 1999, European Radiology.
[21] W. Weintraub,et al. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. , 1999, Journal of the American College of Cardiology.
[22] M. Rich,et al. The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure , 1999, Cardiology.
[23] H. Dargie,et al. The Cardiac Insufficiency Bisoprolol Study II , 1999, The Lancet.
[24] M. Tavakoli,et al. A COST MINIMISATION ANALYSIS OF CARDIAC FAILURE TREATMENT IN THE UK USING CIBIS TRIAL DATA , 1999, International journal of clinical practice.
[25] H A Glick,et al. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. , 1998, American journal of hypertension.
[26] A Briggs,et al. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.
[27] P Carlsson,et al. Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.
[28] R. Willke,et al. Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.
[29] P. Lechat,et al. A Cost-Minimization of Heart Failure Therapy with Bisoprolol in the French Setting: An Analysis from CIBIS Trial Data , 1998, Cardiovascular Drugs and Therapy.
[30] M. Weinstein,et al. Economic Evaluation Alongside Multinational Clinical Trials: Study Considerations for GUSTO iib , 1997, International Journal of Technology Assessment in Health Care.
[31] Andrew M. Jones,et al. Multilevel models and health economics. , 1997, Health economics.
[32] R. Simes,et al. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease. , 1997, Controlled clinical trials.
[33] S. Ball,et al. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. , 1997, PharmacoEconomics.
[34] K. Schulman,et al. Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation , 1996, International Journal of Technology Assessment in Health Care.
[35] H Wedel,et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.
[36] G. Thorgeirsson,et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.
[37] B. Kinosian,et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. , 1995, Journal of cardiac failure.
[38] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[39] M. Drummond,et al. Issues in the Cross-National Assessment of Health Technology , 1992, International Journal of Technology Assessment in Health Care.
[40] B Kinosian,et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. , 1991, The New England journal of medicine.
[41] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[42] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.
[43] D L Sackett,et al. Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. , 1981, The New England journal of medicine.
[44] H. Glick,et al. Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure , 2004, Cardiovascular Drugs and Therapy.
[45] P. Erne,et al. The Economic Efficiency of Amlodipine in the Treatment of Coronary Atherosclerosis—An Analysis Based on the PREVENT Study , 2004, Cardiovascular Drugs and Therapy.
[46] J. Darbà,et al. Cost data assessment in multinational economic evaluations: some theory and review of published studies. , 2003, Applied health economics and health policy.
[47] J Hutton,et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2002, European heart journal.